4//SEC Filing
Anson Management GP LLC 4
Accession 0001193805-23-001317
CIK 0001262104other
Filed
Sep 21, 8:00 PM ET
Accepted
Sep 22, 9:21 PM ET
Size
16.7 KB
Accession
0001193805-23-001317
Insider Transaction Report
Form 4
MEI Pharma, Inc.MEIP
Anson Management GP LLC
10% Owner
Transactions
- Purchase
Common Stock
2023-09-20$6.01/sh+120,000$721,116→ 782,528 total(indirect: See footnotes) - Purchase
Common Stock
2023-09-21$6.46/sh+33,600$217,110→ 816,128 total(indirect: See footnotes)
Winson Bruce Ross
10% Owner
Transactions
- Purchase
Common Stock
2023-09-20$6.01/sh+120,000$721,116→ 782,528 total(indirect: See footnotes) - Purchase
Common Stock
2023-09-21$6.46/sh+33,600$217,110→ 816,128 total(indirect: See footnotes)
Nathoo Amin
10% Owner
Transactions
- Purchase
Common Stock
2023-09-20$6.01/sh+120,000$721,116→ 782,528 total(indirect: See footnotes) - Purchase
Common Stock
2023-09-21$6.46/sh+33,600$217,110→ 816,128 total(indirect: See footnotes)
Kassam Moez
10% Owner
Transactions
- Purchase
Common Stock
2023-09-20$6.01/sh+120,000$721,116→ 782,528 total(indirect: See footnotes) - Purchase
Common Stock
2023-09-21$6.46/sh+33,600$217,110→ 816,128 total(indirect: See footnotes)
Anson Funds Management LP
10% Owner
Transactions
- Purchase
Common Stock
2023-09-20$6.01/sh+120,000$721,116→ 782,528 total(indirect: See footnotes) - Purchase
Common Stock
2023-09-21$6.46/sh+33,600$217,110→ 816,128 total(indirect: See footnotes)
Anson Advisors Inc.
10% Owner
Transactions
- Purchase
Common Stock
2023-09-20$6.01/sh+120,000$721,116→ 782,528 total(indirect: See footnotes) - Purchase
Common Stock
2023-09-21$6.46/sh+33,600$217,110→ 816,128 total(indirect: See footnotes)
Footnotes (3)
- [F1]The filing of this Form 4 shall not be construed as an admission that Anson Funds Management LP ("Anson"), Anson Management GP LLC, the general partner of Anson ("Anson GP"), Bruce R. Winson, the manager of Anson GP, Anson Advisors Inc. ("Anson Advisors"), Amin Nathoo, a director of Anson Advisors, or Moez Kassam, a director of Anson Advisors, is or was for the purposes of Section 16(a) of the Securities Exchange Act of 1934, as amended, or otherwise the beneficial owner of any of the shares of Common Stock, $0.00000002 par value (the "Common Stock"), of MEI Pharma, Inc. (the "Issuer") purchased by Anson Investments Master Fund LP, Anson East Master Fund LP and Anson Opportunities Master Fund LP (collectively, the "Funds"), each advised by Anson and Anson Advisors.
- [F2]Each of the Reporting Persons is a member of a Section 13(d) group that collectively owns more than 10% of the Issuer's outstanding shares of Common Stock. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein except to the extent of his or its pecuniary interest therein.
- [F3]Anson and Anson Advisors hold indirectly 816,128 shares of Common Stock of the Issuer through the Funds, for which Anson and Anson Advisors are the Investment Advisors. Anson GP and Bruce R. Winson report the Common Stock held indirectly by the Funds because, as the general partner of Anson and the manager of Anson GP, respectively, at the time of purchase, they controlled the disposition and voting of the securities. Mr. Nathoo and Mr. Kassam report the Common Stock held indirectly by the Funds because, as the directors of Anson Advisors, at the time of purchase, they controlled the disposition and voting of the securities.
Documents
Issuer
MEI Pharma, Inc.
CIK 0001262104
Entity typeother
IncorporatedTX
Related Parties
1- filerCIK 0001491073
Filing Metadata
- Form type
- 4
- Filed
- Sep 21, 8:00 PM ET
- Accepted
- Sep 22, 9:21 PM ET
- Size
- 16.7 KB